Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
      • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Multiple Sclerosis
      • Systemic Sclerosis
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
    • Education Catalog
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Disease-Specific Indications and Outcomes

  • AML - Adult
  • AML - Pediatric
  • ALL - Adult
  • ALL - Pediatric
  • MDS
  • CML
  • CLL
  • NHL
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Severe Aplastic Anemia & Marrow Failure
  • Sickle Cell Disease
  • Immune Deficiency Diseases
  • Inherited Metabolic Disorders
  • Thalassemia
  • Other Diseases
  • Multiple Sclerosis
  • Systemic Sclerosis
Research Spotlight
  • Review: Role of HCT for CML in the 21st Century

    April 2015

  • Review: HCT for Myeloproliferative Neoplasms in the Era of Tyrosine Kinase Inhibitors

    September 2014

  • Significant Improvement in HCT Survival Over Time

    June 2013

  • Transplant Indications and Outcomes
  • Disease-Specific Indications and Outcomes
  • CML
  • Email
  • Print This Page

Related Resources

  • Subscribe to the Latest CML Research
  • HCT Guidelines App
  • All Outcomes and Statistics Slides

Patient Resources

  • Transplant in CML Patient Fact Sheet (PDF)
  • Transplant Outcomes and Treatment Decisions
  • Transplant Basics Booklet
  • Transplant Basics Videos

Chronic Myeloid Leukemia (CML)

Approximately 8,900 individuals are diagnosed with chronic myeloid leukemia (CML) each year in the United States. This myeloproliferative neoplasm primarily affects older adults, with a median age at diagnosis of 64 years. Approximately 2% of patients diagnosed with CML are under age 20. [1]

Following evidence of significant clinical benefit for CML patients receiving BCR-ABL1 tyrosine kinase inhibitors (TKIs), the use of allogeneic hematopoietic cell transplantation (HCT) for adults with CML is no longer considered first line treatment.

Allogeneic HCT is now indicated for patients with CML who have inadequate hematologic or cytogenetic response, or whose disease develops resistance to TKI treatment or who are intolerant to TKIs, and remains the only curative option. [2]

Advances

Recent research in CML provides new data for clinical decision-making:

  • Pre-transplant imatinib does not lower HCT survival, and may improve it [3]
  • Allogeneic HCT is a viable option for patients who develop imatinib resistance [4]
  • Evaluation for HCT is appropriate soon after diagnosis for CML patients with the T315I mutation [5] 

Outcomes

Review outcomes for allogeneic transplantation in patients with CML below. View additional CML slides showing demographic data and transplant trends.

Data in this section have been prepared by CIBMTR® (Center for International Blood and Marrow Transplant Research), our research program.

Figure 1. CML Survival Over Time, Unrelated HCT

CML Survival Over Time, Unrelated HCT

Download slide "CML Survival Over Time, Unrelated HCT"

Figure 2. CML Survival, Unrelated Marrow HCT, by Disease Status

CML Survival, Unrelated Marrow HCT, by Disease Status

Download slide "CML Survival, Unrelated Marrow HCT, by Disease Status"

Figure 3. CML Survival, Unrelated PBSC HCT, by Disease Status

CML Survival, Unrelated PBSC HCT, by Disease Status

Download slide "CML Survival, Unrelated PBSC HCT, by Disease Status"

Figure 4. CML Survival, Sibling HCT, by Disease Status

CML Survival, Sibling HCT, by Disease Status

Download slide "CML Survival, Sibling HCT, by Disease Status"

Referral Timing Guidelines

These guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for autologous or allogeneic transplantation. [2]

Transplant Consultation Guidelines: CML

  • Inadequate hematologic or cytogenetic/molecular response to tyrosine kinase inhibitor (TKI) therapies
  • Disease progression
  • Intolerance to TKI therapies
  • Accelerated phase
  • Blast crisis (myeloid or lymphoid)
  • T315I mutation

Download as a slide (PPT)
View complete Referral Timing Guidelines

References

  1. SEER Stat Fact Sheets: Chronic Myeloid Leukemia. Website accessed 2 November, 2017. Access
  2. NMDP/Be The Match and ASBMT Recommended Timing for Transplant Consultation. Download (PDF)
  3. Warlick E, Ahn KW, Pedersen TL, et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood. 2012; 119(17): 4083-4090. Access
  4. Jabbour E, Cortes J, Santos FPS, et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011; 117(13): 3641-3647. Access
  5. Velev N, Cortes J, Champlin R, et al. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer. 2010; 116(15): 3631-3637. Access
  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright